Sputnik V Vaccine: Serum Institute seeks permission from DCGI to make Sputnik-V vaccine

Serum Institute of India (SII) can also manufacture the Russian vaccine Sputnik-V in India in the coming days. Serum Institute has sought permission from the Drug Controller General of India (DCGI) for a trial license to manufacture Sputnik-V. The news agency ANI has given this information from its sources.

The Serum Institute, which manufactures the Covid Vaccine Coveshield, has also applied for test analysis and examination. Let us inform you that at present Sputnik V is being manufactured in India by Dr. Reddy's Laboratories. Sputnik V has been approved by the Drug Controller of India for emergency use. The Russian vaccine was registered in India on April 12 under the Emergency Use Authorization process and the use of the Russian vaccine began on May 14. RDIF and Panacea Biotech have agreed to produce 100 million doses of Sputnik V in a year.

Sputnik-V is so far registered in 66 countries with a total population of more than 320 crores. The RDIF and the Gamalya Center have stated that the efficacy of Sputnik V is 97.6 percent, based on an analysis of data on coronavirus infection rates among those vaccinated in Russia with both doses of Sputnik V from December 5 last year to March 31 this year. is based.